Abselion raises £6.6 million led by M Ventures
Series A financing highlights the potential impact of Abselion’s technology for life science research and bioprocess development
Cambridge, UK, December 4, 2024 - Abselion, an innovator in automated analytical instrumentation that simplifies at-line protein quantification, has secured £6.6 million in Series A financing to bring its award-winning Amperia system to market.
This cutting-edge benchtop instrument allows scientists to easily quantify antibodies, AAVs, and other proteins directly from crude samples in as little as one minute, providing critical data on the spot, enhancing efficiency and accuracy in life science research and bioprocessing.
The funding round, led by M Ventures (the strategic, corporate venture capital arm of science and technology company Merck), includes new investors BioProcess 360 Partners and Untitled Ventures, along with BGF, R42 and other existing investors. Oliver Hardick of M Ventures and Chris Major of BioProcess 360 Partners have joined the Company’s new Board of Directors.
Abselion will use the funds to drive the commercialisation and expand the capabilities of its Amperia system. Built on proprietary Redox Electrochemical Detection (RED) technology, Amperia brings a groundbreaking approach to biologics and viral-vector quantification for confident, convenient and cost-effective automated at-line measurement that is accessible to all laboratories and process environments.
“We are delighted to have the support of our investment partners to advance our mission to provide scientists with critical real-time data at the point of need,” says Ruizhi Wang, CEO of Abselion. “The Amperia RED technology delivers the accuracy, speed and agility required for insights that enable confident decision-making, driving bioprocess optimisation and innovation.”
Dr. Oliver Hardick, of M Ventures, commented:
Providing meaningful data as close to the process as possible is a crucial pillar of enabling improved bioprocess development and manufacturing robustness. Abselion’s Amperia system does exactly this by delivering gold-standard insights in minutes that Bioprocess teams typically wait days for. We are thrilled to lead this financing alongside our co-investors and to partner with the Abselion team as they expand this technology and broaden its technical capability through 2025 and beyond. We believe this will disrupt how Process Development operates today, and we invite our colleagues in the industry to reach out to me or the Abselion team to explore this further.
